Skip to content
DraconiticResearch
Search Sources API
186,541 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY-NC-ND 4.0Future Oncology

Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery

14 more authors

Related

  1. 473 Effect of nivolumab with or without relatlimab after stereotactic body radiotherapy in patients with advanced esophagogastric cancer
    Chen Hu, Valsamo Anagnostou, Gavin Pereira +11
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  2. Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
    S. Dalle, P. Saiag, C. Lebbé +13
    European journal of cancer skin cancerPeer-reviewedCC BY-NC-ND 4.0Full text1 citedImmunologyEpidemiology & public healthHAL
  3. Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial
    Ayana T. Ruffin, Crystal L. Mallow, Brian M. Olson +24
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textOncologyCrossref
  4. Salvage nivolumab plus temozolomide associated with improved survival and clinical benefit in refractory melanoma: a retrospective cohort study
    Preethy E. Abraham, Kun Bai, Sheau-Chiann Chen +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  5. Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel
    Stéphane Dalle, Philippe Saiag, Céleste Lebbé +12
    Dermatology and TherapyPeer-reviewedCC BY-NC 4.0Full textOncologyHAL
BibTeX
@article{long2026plain,
  title = {{Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery}},
  author = {Georgina Long and Charlie Garnett-Benson and Sonia Dolfi and Paolo Ascierto and Jun Guo and Ahmad Tarhini and Sunandana Chandra and Eva Muñoz-Couselo and Michele del Vecchio and Andreia Cristina de Melo and Margaret Callahan and Helen Gogas and Reinhard Dummer and Dirk Schadendorf and Peter Koelblinger and Gaelle Quereux and Ioannis Thomas and Jia Xin Yu and Andrew Fisher and Bonnie Wang and Patrick Djidel and Armand Chouzy and Mark Semaan and Bohang Chen and Alicia Cheong and Hussein Tawbi},
  journal = {Future Oncology},
  year = {2026},
  month = sep,
  doi = {10.1080/14796694.2026.2721180},
  url = {https://inserm.hal.science/inserm-05761043v1},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery
AU  - Georgina Long
AU  - Charlie Garnett-Benson
AU  - Sonia Dolfi
AU  - Paolo Ascierto
AU  - Jun Guo
AU  - Ahmad Tarhini
AU  - Sunandana Chandra
AU  - Eva Muñoz-Couselo
AU  - Michele del Vecchio
AU  - Andreia Cristina de Melo
AU  - Margaret Callahan
AU  - Helen Gogas
AU  - Reinhard Dummer
AU  - Dirk Schadendorf
AU  - Peter Koelblinger
AU  - Gaelle Quereux
AU  - Ioannis Thomas
AU  - Jia Xin Yu
AU  - Andrew Fisher
AU  - Bonnie Wang
AU  - Patrick Djidel
AU  - Armand Chouzy
AU  - Mark Semaan
AU  - Bohang Chen
AU  - Alicia Cheong
AU  - Hussein Tawbi
PY  - 2026
DA  - 2026/09/22
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2721180
UR  - https://inserm.hal.science/inserm-05761043v1
SN  - 1479-6694
SN  - 1744-8301
ER  -